Indian pharma firms go local seeking to end reliance on China
Indian drug companies are looking to local makers of so-called active pharmaceutical ingredients (API) or trying to make them in-house in a bid to end their reliance on China as ties between the two countries soured after a deadly border clash last June.
Disruption to supplies from China due to the COVID-19 pandemic was also a major factor driving them to reduce reliance on China in the supply of API.
Executives at India’s Cadila Healthcare, Cipla, Sun Pharmaceutical and Biocon said they were aggressively working on reducing the dependence on the richer rival for raw materials.
Source: Reuters #Feb23
https://www.reuters.com/article/us-health-coronavirus-india-china/indian-pharma-firms-go-local-seeking-to-end-reliance-on-china-idUSKBN2AN124
#India #API #Pharmaceutical #Cipla #Cadila #Biocon #SunPharmaceutical
Indian drug companies are looking to local makers of so-called active pharmaceutical ingredients (API) or trying to make them in-house in a bid to end their reliance on China as ties between the two countries soured after a deadly border clash last June.
Disruption to supplies from China due to the COVID-19 pandemic was also a major factor driving them to reduce reliance on China in the supply of API.
Executives at India’s Cadila Healthcare, Cipla, Sun Pharmaceutical and Biocon said they were aggressively working on reducing the dependence on the richer rival for raw materials.
Source: Reuters #Feb23
https://www.reuters.com/article/us-health-coronavirus-india-china/indian-pharma-firms-go-local-seeking-to-end-reliance-on-china-idUSKBN2AN124
#India #API #Pharmaceutical #Cipla #Cadila #Biocon #SunPharmaceutical